Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Core Viewpoint - Moderna has agreed to pay up to $2.25 billion to settle a patent dispute related to its COVID-19 vaccine technology, resolving all legal actions against it regarding the use of lipid nanoparticle technology [1]. Group 1: Financial Terms of the Settlement - Moderna will make an upfront payment of $950 million in July 2026 [1]. - An additional $1.3 billion payment is contingent on the outcome of a separate legal appeal [1]. Group 2: Market Reaction - Following the announcement, Moderna's shares increased by more than 10% in extended trading [1]. - Arbutus Biopharma's shares rose by 11%, while Roivant Sciences saw a 1% increase [1]. Group 3: Legal Context - The settlement resolves all U.S. and international legal actions accusing Moderna of unauthorized use of lipid nanoparticle technology owned by Genevant Sciences and Arbutus Biopharma in its COVID-19 vaccine, Spikevax [1]. - Lipid nanoparticle technology is crucial for delivering mRNA molecules effectively to human cells [1].